# The state of the art: diagnosis and therapeutic interventions of clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance

## TL;DR

This paper discusses the diagnosis and treatment of CHIP and CCUS, newly classified blood disorders, and explores challenges and solutions in China.

## Contribution

The paper addresses current challenges and proposes potential solutions for the diagnosis and treatment of CHIP and CCUS in China.

## Key findings

- CHIP and CCUS have been officially included in the WHO 2022 and ICC classifications of myeloid neoplasms.
- Three risk prediction models for CHIP and CCUS transformation into myeloid tumors have been proposed recently.
- Clinical trials for therapeutic interventions in CHIP and CCUS are currently underway.

## Abstract

2022年提出的造血淋巴肿瘤WHO分型（WHO 2022）以及髓系肿瘤和急性白血病国际共识分型（ICC）已将潜质未定的克隆性造血（CHIP）和意义未定的克隆性血细胞减少症（CCUS）正式列入了髓系肿瘤分型。最近又相继提出了三个CHIP和CCUS髓系肿瘤转化分险的预测模型，并已开展了CHIP和CCUS干预治疗临床试验。为了规范CHIP和CCUS的诊断和治疗，本文就目前我国面临的挑战以及可能的解决方案做了探讨。